Michael Salsbury Net Worth

Michael Salsbury biography

Michael Salsbury J.D. serves as Independent Director of the Company. He has served as Counsel to Verisma Systems, Inc., a provider of cloud-based automated disclosure management systems, since September 2017. From February 2013 to July 2017, he served as Secretary and General Counsel to Best Doctors, Inc., a provider of expert medical opinions. Mr. Salsbury has more than 25 years' experience as a senior executive with public and private companies and private law practice. Mr. Salsbury received a J.D. and M.B.A. from University of Virginia and a B.A. from Dartmouth College. Our Board believes that Mr. Salsbury's legal expertise and his experience serving as general counsel and secretary of a Fortune 100 corporation qualifies him to serve as a director.

How old is Michael Salsbury?

Michael Salsbury is 70, he's been the Independent Director of NeuroBo Pharmaceuticals Inc since 2019. There are no older and 11 younger executives at NeuroBo Pharmaceuticals Inc.

What's Michael Salsbury's mailing address?

Michael's mailing address filed with the SEC is C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE, MA, 02138.

Insiders trading at NeuroBo Pharmaceuticals Inc

Over the last 5 years, insiders at NeuroBo Pharmaceuticals Inc have traded over 0$ worth of NeuroBo Pharmaceuticals Inc stock and bought 2,544,530 units worth 7,964,379$ . The most active insiders traders include St Co., Ltd Dong A、Tae Heum Jeong、Steven R. Ph.D. Gullans. On average, NeuroBo Pharmaceuticals Inc executives and independent directors trade stock every 0 days with the average trade being worth of 9,541,988$. The most recent stock trade was executed by St Co., Ltd Dong A on 23 June 2024, trading 2,544,530 units of NRBO stock currently worth 7,964,379$.

What does NeuroBo Pharmaceuticals Inc do?

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.

NeuroBo Pharmaceuticals Inc executives and stock owners

NeuroBo Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Dr. Ben Gil Price M.D.,
  CEO & Pres
• Nicola Shannon,
  Vice President - Clinical Operations
• Akash Bakshi,
  Sr. VP & COO
• Michael Miller,
  Investor Relations
• Douglas Swirsky,
  Independent Director
• Michael Salsbury,
  Independent Director
• Jeong Gyun Oh,
  Independent Director
• Tae Heum Jeong,
  Independent Director
• Jason Groves,
  Independent Director
• Mark Versavel,
  Chief Medical Officer
• jeong Gu Kang,
  President, Chief Executive Officer, Interim Chief Financial Officer, Secretary, Treasurer and Director
• Na Yeon Kim,
  Independent Chairman of the Board
• Frank Kondrad,
  VP of Corp. & Bus. Devel.
• Dr. Matthew Bardin BCPS, Pharm.D.,
  Sr. VP of Operations
• Dr. Nadja Mannowetz Ph.D.,
  Sr. VP
• Dr. Andrew Bartynski Ph.D.,
  Sr. VP
• Dr. Gil Price M.D.,
  CEO, Pres & Chief Medical Officer
• Dr. Jeong Gu Kang Ph.D.,
  Pres, CEO, Sec., Interim CFO, Treasurer & Director
• St Co., Ltd Dong A,
  
• Mark A Glickman,
  Director
• Akash Bakshi,
  SVP and COO
• Steven R. Ph.D. Gullans,
  Director
• James Patrick Tursi,
  Director
• Ben Gil Price,
  CEO and President
• D Gordon Strickland,
  Director
• Richard Kang,
  Director
• Inc.E&Healthcare Investment...,
  
• Hyung Heon Kim,
  CEO & President
• Marshall H Woodworth,
  Chief Financial Officer